Article
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood - 3 Sept 2009
Jabbour Elias, Jones Daniel, Kantarjian Hagop M, O'Brien Susan, Tam Constantine, Koller Charles, Burger Jan A, Borthakur Gautam, Wierda William G, Cortes Jorge
Abstract excerpt
Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict long-term clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.